US FDA approves Bayer's blood thinner to prevent repeat strokes
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓The US FDA approved Bayer’s Sunharbo to prevent repeat strokes in patients.
- ✓The drug treats those who had a stroke not caused by heart clots or a mini-stroke.
- ✓Sebastian Guth said, "We believe that we're bringing a practice-changing innovation to the market." Bayer hopes this drug helps their future sales.
Story at a Glance
- Category
- Indian Markets
- Reported By
- Reuters
- Reading Speed
- 2 Minute(s)
- Market Focus
- India Economy
Sign up here.
Sunharbo is approved as a once-daily treatment to prevent another stroke in patients whose previous stroke was not caused by a clot from the heart. It is also approved for patients who have had a high-risk transient ischemic attack, often called a "mini-stroke."
Stroke is a leading cause of death in the United States, and Bayer estimates that each year approximately 795,000 people in the US are likely to experience a stroke.
Bayer is betting on the drug to help offset declining revenue from older blockbuster medicines, such as Xarelto, which has faced competition from cheaper generics after losing patent protection.
"We believe that we're bringing a practice-changing innovation to the market," Sebastian Guth, president of Bayer's US operations, said in an interview.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Reuters
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.